AF Symposium 2026 - Dr Devi Nair (St Bernards Heart & Vascular, US) joins us to discuss early outcomes from the VERITAS Study, evaluating Abbott's next-generation Amulet 360™ Left Atrial Appendage Occluder for stroke prevention in patients with non-valvular atrial fibrillation.

This pivotal study enrolled 400 patients across 34 centers in the United States, Canada, and Europe. Findings presented first at AF Symposium 2026 demonstrated a 93.9% complete closure rate at 45 days with no peridevice leak greater than 3 mm, alongside favorable early safety outcomes including a 99.8% implant success rate and minimal procedural complications through seven-day follow-up.

Interview Questions: 

1. What are the current challenges in left atrial appendage closure, and how does the Amulet 360 address unmet needs in this space?
2. Can you walk us through the design of the VERITAS Study and your patient population?
3. What were the key findings regarding closure rates and early safety outcomes?
4. What are the clinical implications of these findings for patient selection and procedural planning in LAA closure?
5. What are your key take-home messages for electrophysiologists considering this device for their AFib patients?
6. What are the next steps for the VERITAS Study, and when can we expect longer-term efficacy data?

Recorded remotely from Jonesboro, 2026.
Editor: Jordan Rance
Videographer: Oliver Miles, David Ben-Harosh
Support: This is an independent interview produced by Radcliffe Cardiology.